The abstract is read at the publisher; the summary is JClub's.
A whole-blood assay for RNA-targeting therapeutics identifies IL-8 and CXCL10 as candidate biomarkers, enabling immunostimulatory profiling linked to immune-related toxicity signals.
- Why it matters: RNA-targeting drugs can trigger unpredictable innate immune activation that threatens safety and efficacy, creating a need for early, robust screening of drug-induced responses.
- What they did: The assay was tested with FDA-approved drugs and compounds previously withdrawn or discontinued for immune-related adverse effects, using integrated cytokine analysis and parallel murine whole-blood and transgenic pathway-deficient mouse studies.
- The result: Compounds tied to immune-related toxicities produced stronger innate immune responses than therapeutics with established clinical safety records, and pathway-deficient mice supported MAVS, MyD88, TRIF, and UNC93B1 involvement in RNA-induced inflammation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.